The U.S. Food and Drug Administration approved Roche company Genentech’s checkpoint inhibitor Tecentriq (atezolizumab) for first-line treatment for metastatic non-small cell lung cancer with high PD-L1 expression.
The U.S. Food and Drug Administration approved Tecentriq as a standalone therapy for an advanced form of lung cancer.
A late-stage trial testing a combination of Bristol-Myers Squibb Co.’s cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients.
Genentech announced positive data from the Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).
A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations
With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.
